Prostatitis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4451354
  • Report
  • 42 pages
  • P&S Market Research
1 of 3
Prostatitis currently exhibits a growing pipeline with 11 drug candidates.

Prostatitis therapeutics pipeline in 2017

The study analyzed that the prostatitis therapeutics pipeline comprises 11 drug candidates in different stages of development. Prostatitis is an infection or inflammation of the prostate gland that can lead to various syndromes with varying clinical features. The term prostatitis is defined as microscopic inflammation of the tissue of the prostate gland and it occurs due to a broad range of clinical conditions. The National Institutes of Health (NIH) has recognized and defined a classification system for prostatitis in 1999.

Insights on pipeline segments

According to the research findings, one drug candidate has entered the Phase III stage of development in prostatitis therapeutics pipeline.

Drug Candidates with Oral Route of Administration tend to Increase Patient Compliance

The drug candidates of prostatitis pipeline are in different stages of development. Among them, majority of drugs are being developed to be administered by oral route. For instance, Prulifloxacin, a Phase II drug candidate by Angelini Acraf SpA, is being developed to be administered by oral route. Oral route increases the patient compliance as it does not require the assistance of other healthcare professionals. It is the prodrug of ulifloxacin a broad-spectrum fluoroquinolone antibacterial agent that blocks the type II DNA topoisomerase.

Some of the key players developing drugs for the treatment of prostatitis therapeutics include Angelini Acraf SpA, TFPHARMA, and Aquinox Pharmaceuticals, Inc.

Prostatitis Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Prostatitis Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

Chapter 5. Prostatitis Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase III: Drug profiles
5.1.3 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase II: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.4 Discontinued: Drug Candidates
5.5 Inactive: Drug Candidates

Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region for Prostatitis Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for Prostatitis Therapeutics Pipeline

Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Prostatitis Therapeutics Pipeline

Chapter 8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Pipeline Analysis Of Prostatitis Therapeutics, By Company (2017)
Description Of Phase III Drug Candidates
Clinical Trials Of Phase III Drug Candidates
Description Of Phase II Drug Candidates
Clinical Trials Of Phase II Drug Candidates
Discontinued Drug Candidates
Inactive Drug Candidates
Companies - at a Glance

List of Figures
Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Prostatitis Therapeutics Drug Candidates Under Development (2017)
Prostatitis Therapeutics Pipeline Split, By Molecule Type (2017)
Prostatitis Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll